These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23047369)

  • 1. Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India.
    Tandale BV; Pawar SD; Gurav YK; Parkhi SS; Mishra AC
    Hum Vaccin Immunother; 2013 Jan; 9(1):125-7. PubMed ID: 23047369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunogenicity of the pandemic influenza A/H1N1 2009 vaccine among health care workers: influence of prior seasonal influenza vaccination.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Choi WS; Lee J; Jeong HW; Kee SY; Kim WJ
    Clin Vaccine Immunol; 2013 Apr; 20(4):513-6. PubMed ID: 23365206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.
    Strengell M; Ikonen N; Ziegler T; Kantele A; Anttila VJ; Julkunen I
    Influenza Other Respir Viruses; 2013 May; 7(3):431-8. PubMed ID: 22913369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
    Ott U; Sauerbrei A; Lange J; Schäfler A; Walther M; Wolf G; Wutzler P; Zell R; Krumbholz A
    Med Microbiol Immunol; 2012 Aug; 201(3):297-302. PubMed ID: 22350187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.
    Zhou Y; Ng DM; Seto WH; Ip DK; Kwok HK; Ma ES; Ng S; Lau LL; Peiris JS; Cowling BJ
    PLoS One; 2011; 6(11):e27169. PubMed ID: 22102878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.
    Madhun AS; Akselsen PE; Sjursen H; Pedersen G; Svindland S; Nøstbakken JK; Nilsen M; Mohn K; Jul-Larsen A; Smith I; Major D; Wood J; Cox RJ
    Vaccine; 2010 Dec; 29(2):266-73. PubMed ID: 21034828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis.
    Launay O; Boelle PY; Krivine A; Grenet D; Boussaud V; Rémus N; Corvol H; Chedevergne F; Hubert D; Sermet-Gaudelus I;
    Vaccine; 2014 Jul; 32(35):4515-4521. PubMed ID: 24950362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX; Sun N; Ma GY; Wang MM; Sa D; Shi C; Wu JL; Lin X; Xiao Y; Qian YH; Jiang Y; Xie J; Ji YY; Guan HX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):351-4. PubMed ID: 22338222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
    Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations.
    Eidem S; Tete SM; Jul-Larsen Å; Hoschler K; Montomoli E; Brokstad KA; Cox RJ
    Vaccine; 2015 Aug; 33(33):4146-54. PubMed ID: 26057137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
    Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
    Front Immunol; 2018; 9():3103. PubMed ID: 30761157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.